The low-cost compound lignosulfonic acid (LA) exhibits broad-spectrum anti-HIV and anti-HSV activity and has potential for microbicidal applications

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Gordts, Stephanie C ^a   Férir, Geoffrey ^a   D'Huys, Thomas ^a   Petrova, Mariya I ^b,c   Lebeer, Sarah ^b,c   Snoeck, Robert ^a   Andrei, Graciela ^a   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CD209 ANTIGEN; CD69 ANTIGEN; ENFUVIRTIDE; FEGLYMYCIN; GLYCOPROTEIN GP 120; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; LABYRINTOPEPTIN A1; LIGNIN; LIGNOSULFONIC ACID; MARAVIROC; MONOCLONAL ANTIBODY B12; PLERIXAFOR; POLYPEPTIDE ANTIBIOTIC AGENT; PRO 2000; TENOFOVIR; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LIGNOSULFURIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CD4+ T LYMPHOCYTE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; FEMALE; GENE MUTATION; HEK293 CELL LINE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IC50; IN VITRO STUDY; IN VIVO STUDY; LACTOBACILLUS; MICROBICIDAL ACTIVITY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; HERPES GENITALIS; HERPES SIMPLEX VIRUS 2; HIV INFECTIONS; MONONUCLEAR CELL; PHYSIOLOGY; TRANSMISSION; TUMOR CELL LINE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; IN VITRO TECHNIQUES; LEUKOCYTES, MONONUCLEAR; LIGNIN; MICE; VIRUS REPLICATION;

EID: 84940558912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131219     Document Type: Article

References (75)

1. Available: http://www.unaids.org.
2. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007; 21(5):589-98. PMID: 17314521
3. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006; 20(1):73-83. PMID: 16327322
4. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM Jr., Self SG, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One. 2008; 3(5):e2230. doi: 10.1371/journal.pone.0002230 PMID: 18493617
5. Corey L. Synergistic copathogens - HIV-1 and HSV-2. N Engl J Med. 2007; 356(8):854-6. PMID: 17314346
6. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. Plos One. 2015; 10(1):e114989. doi: 10.1371/journal.pone.0114989 PMID: 25608026
7. Baeten J, Celum C. Systemic and Topical Drugs for the Prevention of HIV Infection: Antiretroviral Pre-exposure Prophylaxis. Annu Rev Med. 2013; 64:3.1-3.14.
8. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74. doi: 10.1126/science.1193748 PMID: 20643915
9. Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell host & microbe. 2011; 10(4):379-89.
10. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol. 2004; 30(2):115-33. PMID: 15125867
11. Andrei G, Snoeck R. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis. 2013; 26(6):551-60. doi: 10.1097/QCO.0000000000000015 PMID: 24152761
12. Lisco A, Vanpouille C, Tchesnokov EP, Grivel JC, Biancotto A, Brichacek B, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe. 2008; 4(3):260-70. doi: 10.1016/j.chom.2008.07.008 PMID: 18779052
13. McMahon MA, Parsons TL, Shen L, Siliciano JD, Siliciano RF. Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses. J Virol. 2011; 85(9):4618-22. doi: 10.1128/JVI.02423-10 PMID: 21325417
14. McCubbins N. State-of-the-art of the pulp and paper industry and its environmental protection practices. Environ Protect Serv Econ Tech Rev Rep XVIII. 1983:119-28.
15. Vocac JA, Alphin RS. Effects and mechanism of action of a lignosulphonate on experimental gastric ulceration in rats. Eur J Pharmacol. 1968; 4(1):99-102. PMID: 4878485
16. Vocac JA, Alphin RS. Antiulcerogenic and pepsin inhibitor properties of lignosulfonates. Arch Int Pharmacodyn Ther. 1969; 177(1):150-8. PMID: 4901155
17. Suzuki H, Okubo A, Yamazaki S, Suzuki K, Mitsuya H, Toda S. Inhibition of the infectivity and cytopathic effect of human immunodeficiency virus by water-soluble lignin in an extract of the culture medium of Lentinus edodes mycelia (LEM). Biochem Biophys Res Commun. 1989; 160(1):367-73. PMID: 2469420
18. Qiu M, Wang Q, Chu Y, Yuan Z, Song H, Chen Z, et al. Lignosulfonic acid exhibits broadly anti-HIV-1 activity-potential as a microbicide candidate for the prevention of HIV-1 sexual transmission. PLoS One. 2012; 7(4):e35906. doi: 10.1371/journal.pone.0035906 PMID: 22558266
19. Peden K, Emerman M, Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology. 1991; 185(2):661-72. PMID: 1683726
20. Férir G, Palmer KE, Schols D. Griffithsin, alone and combined with all classes of antiretroviral drugs, potently inhibits HIV cell-cell transmission and destruction of CD4+ T cells. J Antivir Antiretrovir. 2012; 4(4):103-12.
21. Boggiano C, Manel N, Littman DR. Dendritic cell-mediated trans-enhancement of human immunodeficiency virus type 1 infectivity is independent of DC-SIGN. Journal of virology. 2007; 81(5):2519-23. PMID: 17182696
22. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol. 2000; 74(18):8358-67. PMID: 10954535
23. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of virology. 2005; 79(16):10108-25. PMID: 16051804
24. Ferir G, Hanchen A, Francois KO, Hoorelbeke B, Huskens D, Dettner F, et al. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120. Virology. 2012; 433(2):308-19. doi: 10.1016/j.virol.2012.08.007 PMID: 22959895
25. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 1990; 343(6257):470-4. PMID: 1689015
26. Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D. Resistance of HIV-1 to the broadly HIV- 1-neutralizing, anti-carbohydrate antibody 2G12. Virology. 2007; 360(2):294-304. PMID: 17123566
27. de Vreese K, Kofler-Mongold V., Leutgeb C., Weber V., Vermeire K., Schacht S., Anné J., de Clercq E., Datema R., and Werner G. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol. 1996; 70(2):689-96. PMID: 8551604
28. Princen K, Hatse S, Vermeire K, De Clercq E, Schols D. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology. 2004; 1:2. PMID: 15169555
29. Vermeire K, Princen K, Hatse S, De Clercq E, Dey K, Bell TW, et al. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS. 2004; 18(16):2115-25. PMID: 15577644
30. Daelemans D, Pauwels R, De Clercq E, Pannecouque C. A time-of-drug addition approach to target identification of antiviral compounds. Nat Protoc. 2011; 6(6):925-33. doi: 10.1038/nprot.2011.330 PMID: 21637207
31. Férir G, Petrova MI, Andrei G, Huskens D, Hoorelbeke B, Snoeck R, et al. The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications. PLoS One. 2013; 8:e64010. doi: 10.1371/journal.pone.0064010 PMID: 23724015
32. Goel N, Docherty JJ, Fu MM, Zimmerman DH, Rosenthal KS. A modification of the epidermal scarification model of herpes simplex virus infection to achieve a reproducible and uniform progression of disease. Journal of virological methods. 2002; 106(2):153-8. PMID: 12393145
33. De Man JC, Rogosa M, Sharpe ME. A medium for the cultivation of lactobacilli. J Appl Bacteriol. 1960; 23:130-5.
34. Petrova MI, Mathys L, Lebeer S, Noppen S, Van Damme EJ, Tanaka H, et al. Inhibition of infection and transmission of HIV-1 and lack of significant impact on the vaginal commensal lactobacilli by carbohydrate-binding agents. J Antimicrob Chemother. 2013; 68(9):2026-37. doi: 10.1093/jac/dkt152 PMID: 23640125
35. Férir G, Huskens D, Palmer KE, Boudreaux DM, Swanson MD, Markovitz DM, et al. Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV type 2, and selected carbohydrate-binding agent-resistant HIV type 1 strains. AIDS Res Hum Retroviruses. 2012; 28(11):1513-23. doi: 10.1089/AID.2012.0026 PMID: 22607556
36. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drug or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. PMID: 6382953
37. Van Laethem K, Schrooten Y, Lemey P, VW E., De Wit S, Van Ranst M, et al. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods. 2005; 123(1):25-34. PMID: 15582695
38. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol. 2008; 6(11):815-26. doi: 10.1038/nrmicro1972 PMID: 18923409
39. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000; 100(5):587-97. PMID: 10721995
40. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol. 2007; 71(1):3-11. PMID: 17056872
41. Hoorelbeke B, Xue J, LiWang PJ, Balzarini J. Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1. PLoS One. 2013; 8(5):e64132. doi: 10.1371/journal.pone.0064132 PMID: 23741304
42. Kucera LS, Raben D, Iyer N, Ricardo MJ Jr. Herpes simplex virus type 2 infection of unstimulated human T-lymphocytes. Viral Immunol. 1989; 2(1):11-6. PMID: 2545223
43. Kucera LS, Leake E, Iyer N, Raben D, Myrvik QN. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses. 1990; 6(5):641-7. PMID: 1972888
44. Martinelli E, Tharinger H, Frank I, Arthos J, Piatak M Jr, Lifson JD, et al. HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog. 2011; 7(6):e1002109. doi: 10.1371/journal.ppat.1002109 PMID: 21738472
45. de Jong MA, de Witte L, Bolmstedt A, van Kooyk Y, Geijtenbeek TB. Dendritic cells mediate herpes simplex virus infection and transmission through the C-type lectin DC-SIGN. J Gen Virol. 2008; 89(Pt 10):2398-409. doi: 10.1099/vir.0.2008/003129-0 PMID: 18796707
46. Petrova MI, van den Broek M, Balzarini J, Vanderleyden J, Lebeer S. Vaginal microbiota and its role in HIV transmission and infection. FEMS Microbiol Rev. 2013; 37(5):762-92. doi: 10.1111/1574-6976.12029 PMID: 23789590
47. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010; 85(1):91-100. doi: 10.1016/j.antiviral.2009.07.022 PMID: 19683546
48. Shattock RJ, Doms RW. AIDS models: microbicides could learn from vaccines. Nat Med. 2002; 8(5):425. PMID: 11984565
49. Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, Jarvis GA, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother. 2005; 49(9):3607-15. PMID: 16127029
50. Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother. 1996; 40(1):234-6. PMID: 8787913
51. Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. Journal of virology. 2005; 79(20):12692-702. PMID: 16188972
52. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol. 2004; 4(3):199-210. PMID: 15039757
53. Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol. 2009; 83(21):10892-907. doi: 10.1128/JVI.01142-09 PMID: 19692465
54. Esté JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, Desmyter J, et al. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol Pharmacol. 1997; 52(1):98-104. PMID: 9224818
55. He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, et al. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(42):16332-7. doi: 10.1073/pnas.0807335105 PMID: 18852475
56. Neumann T, Hagmann I, Lohrengel S, Heil ML, Derdeyn CA, Krausslich HG, et al. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology. 2005; 333(2):251-62. PMID: 15721359
57. Eggink D, Bontjer I, Langedijk JP, Berkhout B, Sanders RW. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. Journal of virology. 2011; 85(20):10785-97. doi: 10.1128/JVI.05331-11 PMID: 21835789
58. Thurman AR, Doncel GF. Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention. Int J STD AIDS. 2012; 23(9):613-9. doi: 10.1258/ijsa.2012.011356 PMID: 23033511
59. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis. 2008; 198(5):659-63. doi: 10.1086/590668 PMID: 18627246
60. Derby N, Martinelli E, Robbiani M. Myeloid dendritic cells in HIV-1 infection. Curr Opin HIV AIDS. 2011; 6(5):379-84. doi: 10.1097/COH.0b013e3283499d63 PMID: 21743323
61. Stefanidou M, Ramos I, Mas Casullo V, Trepanier JB, Rosenbaum S, Fernandez-Sesma A, et al. Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy. J Virol. 2013; 87(3):1443-53. doi: 10.1128/JVI.01302-12 PMID: 23152529
62. Geijtenbeek TB, van Kooyk Y. Pathogens target DC-SIGN to influence their fate DC-SIGN functions as a pathogen receptor with broad specificity. APMIS. 2003; 111(7-8):698-714. PMID: 12974773
63. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens Nat Rev Immunol. 2003; 3:697-709.
64. Leydet A, El Hachemi H, Boyer B, Lamaty G, Roque JP, Schols D, et al. Polyanion inhibitors of human immunodeficiency virus and other viruses. Part 2. Polymerized anionic surfactants derived from amino acids and dipeptides. J Med Chem. 1996; 39(8):1626-34. PMID: 8648602
65. Agarwal HK, Kumar A, Doncel GF, Parang K. Synthesis, antiviral and contraceptive activities of nucleoside-sodium cellulose sulfate acetate and succinate conjugates. Bioorg Med Chem Lett. 2010; 20(23):6993-7. doi: 10.1016/j.bmcl.2010.09.133 PMID: 20965725
66. Pirrone V, Wigdahl B, Krebs FC. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 2011; 90(3):168-82. doi: 10.1016/j.antiviral.2011.03.176 PMID: 21439325
67. Tollner TL, Overstreet JW, Li MW, Meyers SA, Yudin AI, Salinas ER, et al. Lignosulfonic acid blocks in vitro fertilization of macaque oocytes when sperm are treated either before or after capacitation. J Androl. 2002; 23(6):889-98. PMID: 12399536
68. Tollner TL, Yudin AI, Cherr GN, Overstreet JW. Real-time observations of individual macaque sperm undergoing tight binding and the acrosome reaction on the zona pellucida. Biol Reprod. 2003; 68(2):664-72. PMID: 12533433
69. Zaneveld LJ, Waller DP, Anderson RA, Chany C 2nd, Rencher WF, Feathergill K, et al. Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly (sodium 4-styrenesulfonate). Biol Reprod. 2002; 66(4):886-94. PMID: 11906905
70. Pirrone V, Passic S, Wigdahl B, Krebs FC. Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol J. 2012; 9:33. doi: 10.1186/1743-422X-9-33 PMID: 22281044
71. Segarra TJ, Fakioglu E, Cheshenko N, Wilson SS, Mesquita PM, Doncel GF, et al. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One. 2011; 6(11):e27675. doi: 10.1371/journal.pone.0027675 PMID: 22096611
72. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis. 2009; 200(4):599-608. doi: 10.1086/600867 PMID: 19586414
73. Huskens D, Vermeire K, Profy AT, Schols D. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral research. 2009; 84(1):38-47. doi: 10.1016/j.antiviral.2009.07.013 PMID: 19664662
74. Abdool Karim S, Richardson B, Ramjee G, Hoffman I, Chirenje Z, Taha T, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011; 25 (7):957-66. doi: 10.1097/QAD.0b013e32834541d9 PMID: 21330907
75. Bourne N, Bernstein DI, Ireland J, Sonderfan AJ, Profy AT, Stanberry LR. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis. 1999; 180(1):203-5. PMID: 10353881